Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 24;14:17588359211070643. doi: 10.1177/17588359211070643

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 8. — Association between KRAS MMB and therapeutic response after four cycles of first-line treatment. (a) Summary of mutation sites of KRAS identified by individual patient after four cycles of first-line treatment. (b) KRAS MMB was lower in non-PD patients than PD patients. (c) The distribution of patients with PD/non-PD in MMB-high and MMB-low subgroups. (d) PFS was longer in patients with low-KRAS MMB than patients with high-KRAS MMB. (e) OS was longer in patients with low-KRAS MMB than patients with high-KRAS MMB.